IL13 and type 2 diabetes mellitus: Thiazolidinediones (TZDs), an FDA-approved class of PPAR agonists used to manage type 2 diabetes, improved the outcomes of anti-IL-4/IL-13 for treating AD in obese mice by reducing immunological misfiring [109].